🚀 VC round data is live in beta, check it out!
Eczacıbaşı İlaç Valuation Multiples
Discover revenue and EBITDA valuation multiples for Eczacıbaşı İlaç and similar public comparables like Natco Pharma, Hanall Biopharma, Olema Pharmaceuticals, Syndax and more.
Eczacıbaşı İlaç Overview
About Eczacıbaşı İlaç
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is a Turkey-based company that operates in the drug business. It is mainly involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.
Founded
1951
HQ
Employees
14
Website
Sectors
Financials (FY)
EV
$2B
Eczacıbaşı İlaç Financials
Eczacıbaşı İlaç reported last fiscal year revenue of $199M and EBITDA of $73M.
In the same fiscal year, Eczacıbaşı İlaç generated $68M in gross profit, $73M in EBITDA, and $23M in net income.
Eczacıbaşı İlaç P&L
In the most recent fiscal year, Eczacıbaşı İlaç reported revenue of $199M and EBITDA of $73M.
Eczacıbaşı İlaç expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $199M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $68M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 34% | XXX | XXX | XXX |
| EBITDA | — | XXX | $73M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1%) | XXX | XXX | XXX |
| Net Profit | — | XXX | $23M | XXX | XXX | XXX |
| Net Margin | — | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $16M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Eczacıbaşı İlaç Stock Performance
Eczacıbaşı İlaç has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Eczacıbaşı İlaç's stock price is $2.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | (0.2%) | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEczacıbaşı İlaç Valuation Multiples
Eczacıbaşı İlaç trades at 9.5x EV/Revenue multiple, and 26.0x EV/EBITDA.
Eczacıbaşı İlaç Financial Valuation Multiples
As of March 7, 2026, Eczacıbaşı İlaç has market cap of $2B and EV of $2B.
Equity research analysts estimate Eczacıbaşı İlaç's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eczacıbaşı İlaç has a P/E ratio of 82.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 9.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 26.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1554.9x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 27.9x | XXX | XXX | XXX |
| P/E | — | XXX | 82.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 51.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eczacıbaşı İlaç Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eczacıbaşı İlaç Margins & Growth Rates
Eczacıbaşı İlaç's revenue in the last fiscal year grew by 35%.
Eczacıbaşı İlaç Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (28%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Eczacıbaşı İlaç Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Natco Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Hanall Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Olema Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Syndax | XXX | XXX | XXX | XXX | XXX | XXX |
| Bora Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eczacıbaşı İlaç M&A Activity
Eczacıbaşı İlaç acquired XXX companies to date.
Last acquisition by Eczacıbaşı İlaç was on XXXXXXXX, XXXXX. Eczacıbaşı İlaç acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Eczacıbaşı İlaç
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEczacıbaşı İlaç Investment Activity
Eczacıbaşı İlaç invested in XXX companies to date.
Eczacıbaşı İlaç made its latest investment on XXXXXXXX, XXXXX. Eczacıbaşı İlaç invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Eczacıbaşı İlaç
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eczacıbaşı İlaç
| When was Eczacıbaşı İlaç founded? | Eczacıbaşı İlaç was founded in 1951. |
| Where is Eczacıbaşı İlaç headquartered? | Eczacıbaşı İlaç is headquartered in Turkey. |
| How many employees does Eczacıbaşı İlaç have? | As of today, Eczacıbaşı İlaç has over 14 employees. |
| Is Eczacıbaşı İlaç publicly listed? | Yes, Eczacıbaşı İlaç is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Eczacıbaşı İlaç? | Eczacıbaşı İlaç trades under ECILC ticker. |
| When did Eczacıbaşı İlaç go public? | Eczacıbaşı İlaç went public in 1990. |
| Who are competitors of Eczacıbaşı İlaç? | Eczacıbaşı İlaç main competitors are Natco Pharma, Hanall Biopharma, Olema Pharmaceuticals, Syndax. |
| What is the current market cap of Eczacıbaşı İlaç? | Eczacıbaşı İlaç's current market cap is $2B. |
| What is the current revenue of Eczacıbaşı İlaç? | Eczacıbaşı İlaç's last fiscal year revenue is $199M. |
| What is the current EV/Revenue multiple of Eczacıbaşı İlaç? | Current revenue multiple of Eczacıbaşı İlaç is 9.5x. |
| Is Eczacıbaşı İlaç profitable? | No, Eczacıbaşı İlaç is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.